Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473236 | 0.81 | HTR6 (1.00) | HTR6 | |
| SCHEMBL5483714 | 0.76 | HTR6 (0.69) | HTR6GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL14544375 | 0.75 | HTR6 (0.49) | HTR6ALDH1A1SMN1; SMN2KMT2ATDP1 | |
| SCHEMBL14521402 | 0.67 | HTR6 (1.00) | HTR6 | |
| SCHEMBL4480337 | 0.64 | HTR6 (0.76) | HTR6ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5479746 | 0.64 | HTR6 (0.74) | HTR6 | |
| SCHEMBL23320099 | 0.64 | GRM5 (0.32) | — | |
| SCHEMBL4473244 | 0.62 | HTR6 (0.70) | HTR6PKMPKLRPOLB | |
| SCHEMBL1136439 | 0.62 | HTR6 (1.00) | HTR6 | |
| SCHEMBL13264477 | 0.62 | KMT2A (0.64) | HTR6GAAALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377931-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-31 | — | — | US | disclosed |
| EP-1694656-B1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| EP-1694656-B1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-7202241-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202241-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202241-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1694656-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058847-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | BERGER JACOB (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050124613-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | disclosed |
| US-6867204-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | F12, CYP4X1, CYP3A5 | HTR6 2321/4885GAA 1971/4885ALDH1A1 376/4885 |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | F12, HAX1, CYP4X1 | HTR6 2220/4885GAA 2097/4885ALDH1A1 369/4885 |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | CYP3A5, CYP4X1, XDH | HTR6 1363/4885GAA 1264/4885ALDH1A1 256/4885 |
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | F12, CYP4X1, CYP3A5 | HTR6 2321/4885GAA 1971/4885ALDH1A1 376/4885 |
| US-20050124613-A1 | Benzoxazine derivatives and uses thereof | XDH, CYP4X1, CYP2C9 | HTR6 1872/4885GAA 1372/4885ALDH1A1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.